Soins de support LE DECLIC-EPRI (IC 2019-06) DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI. Paris, Saint-Cloud EVELYNE RENAULT TESSIER
Pédiatrie Tumeurs solides INFORM2 - NIVENT (IC 2018-07) INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies Paris GUDRUN SCHLEIERMACHER
Recherches "plusieurs pathologies" EPITOP 01 Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial Saint-Cloud MICHAEL BRINGUIER
Pédiatrie Tumeurs solides GSK213406 A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of;Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours Paris FRANCOIS DOZ
Recherches "plusieurs pathologies" NANORAD2 Radiotherapy of Multiple Brain Metastases Using AGuIX® Gadolinium-chelated Polysiloxane Based Nanoparticles: a Prospective Randomized Phase II Clinical Trial. Saint-Cloud JOELLE OTZ
Recherches "plusieurs pathologies" BRAINSTORM A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours - BrainStorm Program Paris
Soins de support ES4-UIC (IC 2020-18) Prospective, Observational Study Evaluating the Feasibility of a Systematic and Standardized Assessment of Supportive Care Needs in Patients With Advanced Solid Cancer at the Inclusion in a Therapeutic Trial at the Institut Curie Paris PAULINE DU RUSQUEC
Pédiatrie Tumeurs solides iMATRIX-Alectinib (GO42286) A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available. Paris FRANCOIS DOZ
Pédiatrie Neuroblastomes NANT 2015-02 (IC 2018-05) Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma Paris GUDRUN SCHLEIERMACHER